Anteris Technologies Global Corp AVR

$4.99 -0.10 (-1.96%)

Valuation

Market cap
507,938,000
Revenue TTM
$1,910,000
Net income TTM
$-94,140,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-4,928.80%
Debt to equity
0.00

Trading

Volume
1,537,800
Avg volume
1,319,226
Day's range
$4.92 – $5.18
Shares out
97,493,000
Stochastic %K
15%
Beta
2.02
Analysts
Moderate Buy
Price target
$14.00

Price

Company profile

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissu...

Show more

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.

Industry
Medical Devices
Sector
Healthcare
Phone
61 7 3152 3200
Website
https://anteristech.com
Address
Toowong Tower, Level 3, Suite 302 9 Sherwood Road, Toowong, Australia

Latest news

Stocktwits

Idvst8 Nov 19, 6:19 PM
$AVR - For those who have a time horizon, beyond a few weeks, this is a very attractive level. May see $4 handle on macro market erotion.......but this puppy is a great Spec Play
1 replies
XxGodFatherxX Nov 17, 8:49 PM 0 replies
Templar57 Nov 17, 11:18 AM
$AVR DurAVR’s ComASUR delivery system could give physicians a second reason to choose DurAVR alongside its hemodynamics: more predictable placement and easier coronary access down the road. If Anteris can show those benefits consistently across PARADIGM sites and operators, the delivery system could matter as much to adoption as the early valve data suggest the valve itself might.
1 replies
Templar57 Nov 16, 1:32 PM
$AVR Reported institutional ownership of AVR is above 75.09%, and insiders own another 4.9%. That puts their combined stake at roughly 80%. To me, that’s a striking level of ownership for a company whose DurAVR valve is still investigational.
1 replies
Idvst8 Nov 13, 5:49 PM
$AVR - Will be keeping a close eye here for more Cheapies in coming weeks
1 replies
XxGodFatherxX Nov 13, 4:54 PM
$AVR fascinating how molested a de-risked company can be
1 replies
XxGodFatherxX Nov 13, 4:38 PM 0 replies
Idvst8 Nov 13, 3:05 PM
$AVR - Dirt Cheap !!!
0 replies